Advances in the treatment of bladder cancer with oncolytic virus
10.3760/cma.j.cn112330-20200424-00323
- VernacularTitle:溶瘤病毒在膀胱癌治疗中的研究现状与进展
- Author:
Bingqing SHANG
1
;
Jianzhong SHOU
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院 北京协和医学院肿瘤医院泌尿外科，北京 100021
- From:
Chinese Journal of Urology
2020;41(8):633-636
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer is the most common malignant tumor in urinary system. Immunotherapy, as a new treatment modality, has recently achieved great success in urothelial cancer. As a hotspot of immunotherapy, oncolytic virus can promote anti-tumor response by specifically destroying tumor cells and activating specific anti-tumor immune response. At present, oncolytic virus has made a great breakthrough in the treatment of bladder cancer, especially in the treatment of NMIBC. Oncolytic viruses, including adenovirus, coxsackie virus, vaccinia virus and herpes simplex virus, have shown good safety and effectiveness in a number of clinical trials for bladder cancer treated by intravesical instillation. Especially when recombinant adenovirus interferon α is used in the phase Ⅲ clinical trial of bladder cancer, up to 53% of the patients have achieved complete response at the third months, but there was no grade Ⅳ/Ⅴ adverse reaction. In this paper, the latest progress of research on oncolytic virus in the treatment of bladder cancer was reviewed.
